Study: NCT00436826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Participants were administered with cladribine tablets orally as cumulative dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Participants were administered with cladribine tablets orally as cumulative dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Participants were administered with cladribine tablets orally as cumulative dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cladribine
Description: Participants were administered with cladribine tablets orally as cumulative dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants were administered with placebo orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants were administered with placebo orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants were administered with placebo orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-beta (IFN-beta)
Description: Participants received IFN-beta therapy (Rebif® new formulation \[RNF\] 44 microgram \[mcg\] three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) during both DB period of 96 weeks and OL extension period of 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-beta (IFN-beta)
Description: Participants received IFN-beta therapy (Rebif® new formulation \[RNF\] 44 microgram \[mcg\] three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) during both DB period of 96 weeks and OL extension period of 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-beta (IFN-beta)
Description: Participants received IFN-beta therapy (Rebif® new formulation \[RNF\] 44 microgram \[mcg\] three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) during both DB period of 96 weeks and OL extension period of 48 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Interferon-beta (IFN-beta)
Description: Participants received IFN-beta therapy (Rebif® new formulation \[RNF\] 44 microgram \[mcg\] three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) during both DB period of 96 weeks and OL extension period of 48 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Interferon-beta (IFN-beta)
Description: Participants received IFN-beta therapy (Rebif® new formulation \[RNF\] 44 microgram \[mcg\] three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) during both DB period of 96 weeks and OL extension period of 48 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Interferon-beta (IFN-beta)
Description: Participants received IFN-beta therapy (Rebif® new formulation \[RNF\] 44 microgram \[mcg\] three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) during both DB period of 96 weeks and OL extension period of 48 weeks.